|
| All patients (n = 45) | Mild (n = 15) | Moderate (n = 18) | Severe (n = 12) | p values |
| Systolic pressure, median (IQR), mmHg | 123 (112 - 152) | 116 (112 - 137) | 124 (113 - 147) | 115 (88 - 125) | 0.469 |
| Respiratory rate, median (IQR) | 30.5 (30 - 35) | 30 (29 - 31) | 34.5 (30.3 - 36.5) | 33 (29.3 - 39) | 0.039 |
| PH, median (IQR) | 7.45 (7.42 - 7.48) | 7.42 (7.4 - 7.43) | 7.47 (7.45 - 7.49) | 7.47 (7.42 - 7.48) | 0.001 |
| PO2, median (IQR) | 68 (55.5 - 75) | 75 (72 - 80) | 66.4 (59.5 - 74.3) | 53.2 (45.6 - 56.8) | <0.001 |
| PCO2, median (IQR) | 35.6 (31.8 - 41.1) | 40.2 (32.8 - 41.4) | 34.3 (31.6 - 37.2) | 35.5 (30.4 - 41.2) | 0.363 |
| PO2/FiO2, median (IQR) | 150 (92.7 - 218) | 228 (219.5 - 245) | 138.5 (106.3 - 168.4) | 78.3 (72.5 - 86.8) | <0.001 |
| Acute Physiology and Chronic Health Evaluation II | 16 (12 - 24) | 12 (10 - 16) | 16 (12 - 20) | 28 (23 - 37) | <0.001 |
| Glasgow Coma Scale score | 14 (9 - 15) | 15 (14 - 15) | 12.5 (11.25 - 15) | 8 (7 - 15) | 0.025 |
| Sequential Organ Failure Assessment scores | 4 (3 - 6) | 3 (2.5 - 4) | 4 (3 - 5) | 7 (5.75, 9.25) | <0.001 |
| Comorbidities |
|
|
|
|
|
| Acute kidney injury | 7 (15.6%) | 2 (13.3%) | 2 (11.1%) | 3 (25%) | 0.592 |
| Cardiac injury | 9 (20%) | 1 (6.7%) | 2 (11.1%) | 6 (50.0%) | 0.013 |
| Liver dysfunction | 20 (44.4%) | 4 (26.7%) | 11 (61.1%) | 5 (41.7%) | 0.138 |
| Hyperglycaemia | 12 (26.7%) | 1 (6.7%) | 6 (33.3%) | 5 (41.7%) | 0.072 |
| Pneumothorax | 2 (4.4%) | 0 (0%) | 0 (0%) | 2 (16.7%) | 0.067 |
| Shock | 5 (11.1%) | 0 (0%) | 1 (5.6%) | 4 (33.4%) | 0.026 |
| Treatment |
|
|
|
|
|
| High flow nasal cannula | 24 (53.3%) | 8 (53.3%) | 10 (55.6%) | 6 (50.0%) | >0.99 |
| Mechanical ventilation | 45 (100%) | 15 (100%) | 18 (100%) | 12 (100%) | >0.99 |
| Non-invasive | 40 (88.9%) | 15 (100%) | 16 (88.9%) | 9 (75.0%) | 0.133 |
| Invasive | 9 (20%) | 0 (0%) | 3 (16.7%) | 6 (50%) | 0.005 |
| Prone position ventilation | 15 (33.3%) | 1 (6.7%) | 6 (33.3%) | 9 (75.0%) | 0.001 |
| Antiviral agents | 45 (100%) | 15 (100%) | 18 (100%) | 12 (100%) | >0.99 |
| Antibacterial agents | 6 (13.3%) | 0 (0%) | 1 (5.6%) | 5 (41.7%) | 0.004 |
| Glucocorticoids | 38 (84.4%) | 12 (80.0%) | 15 (83.3%) | 11 (91.7%) | 0.774 |
| Inhibitor | 4 (8.9%) | 2 (13.3%) | 2 (11.1%) | 0 (0%) | 0.551 |
| Interferon | 8 (17.8%) | 0 (0%) | 3 (16.7%) | 5 (41.7%) | 0.017 |
| Immunoglobulin | 32 (71.1%) | 7 (46.7%) | 15 (83.3%) | 10 (83.3%) | 0.058 |
| Prognosis |
|
|
|
|
|
| Hospitalisation | 22 (48.9%) | 5 (33.3%) | 11 (61.1%) | 6 (50%) | 0.289 |
| Discharge | 16 (35.6%) | 9 (60.0%) | 6 (33.3%) | 1 (8.3%) | 0.02 |
| Death | 7 (15.6%) | 1 (6.7%) | 1 (5.6%) | 5 (41.7%) | 0.018 |